Management of bleeding and transfusion during liver transplantation before and after the introduction of a rotational thromboelastometry–based algorithm

Stéphanie Roullet, Geneviève Freyburger, Maximilien Cruc, Alice Quinart, Laurent Stecken, Magali Audy, Laurence Chiche, François Sztark – 20 October 2014 – Orthotopic liver transplantation (OLT) remains a potentially hemorrhagic procedure. Rotational thromboelastometry (ROTEM) is a point‐of‐care device used to monitor coagulation during OLT. Whether it allows blood loss and transfusions to be reduced during OLT remains controversial. Excellent correlations and predictive values have been found between ROTEM parameters and fibrinogen.

Sofosbuvir with peginterferon‐ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis

Eric Lawitz, Fred Poordad, Diana M. Brainard, Robert H. Hyland, Di An, Hadas Dvory‐Sobol, William T. Symonds, John G. McHutchison, Fernando E. Membreno – 16 October 2014 – Sofosbuvir (SOF) in combination with ribavirin (RBV) for 12 or 24 weeks is the current standard of care for patients infected with hepatitis C virus (HCV) genotypes 2 and 3, respectively. However, in clinical trials treatment‐experienced patients, particularly those with cirrhosis, had suboptimal sustained virological response (SVR) rates.

Sofosbuvir with peginterferon‐ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis

Eric Lawitz, Fred Poordad, Diana M. Brainard, Robert H. Hyland, Di An, Hadas Dvory‐Sobol, William T. Symonds, John G. McHutchison, Fernando E. Membreno – 16 October 2014 – Sofosbuvir (SOF) in combination with ribavirin (RBV) for 12 or 24 weeks is the current standard of care for patients infected with hepatitis C virus (HCV) genotypes 2 and 3, respectively. However, in clinical trials treatment‐experienced patients, particularly those with cirrhosis, had suboptimal sustained virological response (SVR) rates.

Concordance of sustained virological response 4, 12, and 24 weeks post‐treatment with sofosbuvir‐containing regimens for hepatitis C virus

Eric M. Yoshida, Mark S. Sulkowski, Edward J. Gane, Robert W. Herring, Vlad Ratziu, Xiao Ding, Jing Wang, Shu‐Min Chuang, Julie Ma, John McNally, Luisa M. Stamm, Diana M. Brainard, William T. Symonds, John G. McHutchison, Kimberly L. Beavers, Ira M. Jacobson, K.

Concordance of sustained virological response 4, 12, and 24 weeks post‐treatment with sofosbuvir‐containing regimens for hepatitis C virus

Eric M. Yoshida, Mark S. Sulkowski, Edward J. Gane, Robert W. Herring, Vlad Ratziu, Xiao Ding, Jing Wang, Shu‐Min Chuang, Julie Ma, John McNally, Luisa M. Stamm, Diana M. Brainard, William T. Symonds, John G. McHutchison, Kimberly L. Beavers, Ira M. Jacobson, K.

Medication misuse, nonadherence, and clinical outcomes among liver transplant recipients

Marina Serper, Rachel E. Patzer, Peter P. Reese, Kamila Przytula, Rachel Koval, Daniela P. Ladner, Josh Levitsky, Michael M. Abecassis, Michael S. Wolf – 13 October 2014 – Medication nonadherence after liver transplantation (LT) is associated with adverse clinical outcomes such as graft rejection and graft loss. Few studies have examined nonadherence and its impact on clinical outcomes in LT.

Mitochondrial dysfunction in steatotic rat livers occurs because a defect in complex i makes the liver susceptible to prolonged cold ischemia

Michael J. J. Chu, Anthony J. R. Hickey, Yannan Jiang, Amorita Petzer, Adam S. J. R. Bartlett, Anthony R. J. Phillips – 13 October 2014 – Steatotic livers are susceptible to cold ischemia, which is thought to be secondary to mitochondrial dysfunction. Ischemic preconditioning (IPC) has been reported to improve liver function in the setting of warm ischemia/reperfusion injury, but the effect of IPC on steatotic liver mitochondrial function (MF) with cold ischemia has not been previously evaluated.

Subscribe to